STOCKHOLM, July 3, 2024 /PRNewswire/ -- Sobi plans to publish its report for the second quarter of 2024 on 16 July 2024 at 08:00 CEST.
Sobi gets EU okay for long-acting haemophilia A drug
STOCKHOLM, May 24, 2024 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals, Inc. today announced positive one-year results from the phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.
FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS
Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.
STOCKHOLM, May 14, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 14 May 2024. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Sobi has received approval for an indication extension from the European Commission for Aspaveli to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
STOCKHOLM, May 8, 2024 /PRNewswire/ -- Sobi® today announced that the European Commission (EC) has approved an indication extension for Aspaveli® (pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
STOCKHOLM, May 8, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.